Pyrazol-4-yl-pyridine M4 Allosteric Modulators for Selective CNS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current muscarinic agonists for treating Alzheimer's disease and schizophrenia face challenges due to lack of receptor subtype selectivity, leading to dose-limiting side effects such as gastrointestinal disturbances and cardiovascular issues.
Innovation Solution
Development of pyrazol-4-yl-pyridine compounds that act as selective allosteric modulators of the M4 muscarinic acetylcholine receptor, enhancing receptor activity without the need for orthosteric agonism, thereby reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective muscarinic agonists are used to treat Alzheimer's disease and schizophrenia, then cognitive and psychiatric symptoms can be improved, but dose-limiting side effects occur including gastrointestinal disturbances and cardiovascular issues
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (pyrazol-4-yl-pyridine core with particular substituents) that confer selective affinity for M4 receptors over other muscarinic subtypes. This structural differentiation enables the drug to act locally on M4 receptors in the CNS while avoiding off-target effects on M1-M3 and M5 receptors, thereby resolving the contradiction between therapeutic efficacy and side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituents at positions R1-R7, ring structures A) to optimize the balance between M4 selectivity and agonist activity. By adjusting these chemical parameters, the compounds achieve sufficient potency at M4 receptors while maintaining selectivity, thus improving the therapeutic window and reducing dose-limiting side effects
2Reliability
If muscarinic agonists are used to activate mAChRs, then cholinergic signaling can be potentiated, but lack of receptor subtype selectivity results in disturbed gastrointestinal motility and other side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (pyrazol-4-yl-pyridine core with particular substituents) that confer selective affinity for M4 receptors over other muscarinic subtypes. This structural differentiation enables the drug to act locally on M4 receptors in the CNS while avoiding off-target effects on M1-M3 and M5 receptors, thereby resolving the contradiction between therapeutic efficacy and side effects
Solution Approach 2:
The patent employs the intermediary principle by using M4-selective agonists as a bridge between acetylcholinesterase inhibitors and direct non-selective muscarinic agonists. These compounds selectively activate M4 receptors to produce cognitive and psychiatric benefits while serving as an intermediary that avoids the gastrointestinal side effects associated with non-selective agonism, thus potentiating cholinergic signaling without harmful effects
Data Source
AI summary
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.